(Q37963718)

26 August 2017

title

Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders (English)

1 reference

26 August 2017

1 reference

1 reference

1

Jaime Kulisevsky

1 reference

26 August 2017

Michael Poyurovsky

2

1 reference

26 August 2017

publication date

30 November 2011

1 reference

26 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

European Neurology

1 reference

26 August 2017

volume

67

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

4-11

1 reference

Treatment of Parkinson's disease : what's on the horizon?

26 August 2017

cites work

1 reference

Pathophysiology of parkinsonism

21 January 2018

1 reference

Circuits and circuit disorders of the basal ganglia

21 January 2018

1 reference

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications

21 January 2018

1 reference

Adenosine receptors and the central nervous system.

21 January 2018

1 reference

Adenosine receptors in the nervous system: pathophysiological implications.

21 January 2018

1 reference

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

21 January 2018

1 reference

Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia

21 January 2018

1 reference

Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.

21 January 2018

1 reference

Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders

21 January 2018

1 reference

Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.

21 January 2018

1 reference

Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia

21 January 2018

1 reference

Progress in the pathogenesis and genetics of Parkinson's disease

21 January 2018

1 reference

Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease.

21 January 2018

1 reference

An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease

21 January 2018

1 reference

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

21 January 2018

1 reference

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

21 January 2018

1 reference

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

Adenosine A2A receptors and Parkinson's disease.

21 January 2018

1 reference

Neurological complications of psychiatric drugs: clinical features and management

21 January 2018

1 reference

An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy

21 January 2018

1 reference

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects

21 January 2018

1 reference

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction

21 January 2018

1 reference

Acute antipsychotic-induced akathisia revisited

21 January 2018

1 reference

Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.

21 January 2018

1 reference

Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.

21 January 2018

1 reference

Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia

21 January 2018

1 reference

Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats

21 January 2018

1 reference

Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration

21 January 2018

1 reference

Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.

21 January 2018

1 reference

Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.

21 January 2018

1 reference

A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease

21 January 2018

1 reference

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias

21 January 2018

1 reference

Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.

21 January 2018

1 reference

Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats

21 January 2018

1 reference

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

21 January 2018

1 reference

The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.

21 January 2018

1 reference

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

21 January 2018

1 reference

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

21 January 2018

1 reference

SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats

21 January 2018

1 reference

Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide.

21 January 2018

1 reference

The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure

21 January 2018

1 reference

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

21 January 2018

1 reference

A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease

21 January 2018

1 reference

The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

21 January 2018

1 reference

Movement disorders induced in monkeys by chronic haloperidol treatment

21 January 2018

1 reference

Haloperidol-induced tardive dyskinesia in monkeys

21 January 2018

1 reference

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000331768

1 reference

26 August 2017

1 reference